Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 338

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer

Shaffer, David R., Leversha, Margaret A., Danila, Daniel C., Lin, Oscar, Gonzalez-Espinoza, Rita, Gu, Bin, Anand, Aseem, Smith, Katherine, Maslak, Peter, Doyle, Gerald V., Terstappen, Leon W.M.M., Lilja, Hans, Heller, Glenn, Fleisher, Martin, Scher, Howard I.·2007·Clinical Cancer Research

Abstract

Purpose: To better direct targeted therapies to the patients with tumors that express the target, there is an urgent need for blood-based assays that provide expression information on a consistent basis in real time with minimal patient discomfort. We aimed to use immunomagnetic-capture technology to isolate and analyze circulating tumor cells (CTC) from small volumes of peripheral blood of patients with advanced prostate cancer. Experimental Design: Blood was collected from 63 patients with metastatic prostate cancer. CTCs were isolated by the Cell Search system, which uses antibodies to epithelial cell adhesion marker and immunomagnetic capture. CTCs were defined as nucleated cells positive for cytokeratins and negative for CD45. Captured cells were analyzed by immunofluorescence, Papanicolau staining, and fluorescence in situ hybridization. Results: Most patients (65%) had 5 or more CTCs per 7.5 mL blood sample. Cell counts were consistent between laboratories (c = 0.99) and did not change significantly over 72 or 96 h of storage before processing (c = 0.99). Their identity as prostate cancer cells was confirmed by conventional cytologic analysis. Molecular profiling, including analysis of epidermal growth factor receptor (EGFR) expression, chromosome ploidy, and androgen receptor (AR) gene amplification, was possible for all prostate cancer patients with ≥5 CTCs. Conclusions: The analysis of cancer-related alterations at the DNA and protein level from CTCs is feasible in a hospital-based clinical laboratory. The alterations observed in EGFR and AR suggest that the methodology may have a role in clinical decision making.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-06-2701

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 338

Metadata

Authors
Shaffer, D. R., Leversha, M. A., Danila, D. C., Lin, O., Gonzalez-Espinoza, R., Gu, B., Anand, A., Smith, K., Maslak, P., Doyle, G. V., Terstappen, L. W. M. M., Lilja, H., Heller, G., Fleisher, M., & Scher, H. I.
Venue
Clinical Cancer Research
Published
2007-04-01
Volume
13
Issue
7
Pages
2023-2029
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2144769242
Cited by
338
References
32
FWCI
20.57
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-06-2701
The paper
Shaffer, D. R., Leversha, M. A., Danila, D. C., Lin, O., Gonzalez-Espinoza, R., Gu, B., Anand, A., Smith, K., Maslak, P., Doyle, G. V., Terstappen, L. W. M. M., Lilja, H., Heller, G., Fleisher, M., & Scher, H. I. (2007). Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-06-2701

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.